Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma

Not Applicable

Completed

• Conditions: Clinical T1 Renal Mass
• Interventions: Other: Preoperative 99mTc-Sestamibi SPECT/CT

• Registration Number: NCT02160925
• Lead Sponsor: Johns Hopkins University

Brief Summary

The objective of this study is to investigate the utility of 99mTc-sestamibi SPECT/CT imaging for the diagnosis of renal oncocytomas.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-05
• Study First Submitted: 2014-06-06
• Study First Submitted QC: 2014-06-09
• Study First Posted: 2014-06-11
• Primary Completion: 2018-06
• Study Completion: 2018-06
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-29
• Last Update Posted: 2019-07-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 125

Inclusion Criteria

• Presence of a solid enhancing cT1 renal mass detected on cross-sectional imaging
• Scheduled to undergo surgery with either partial or radical nephrectomy
• Age ≥18 years

Exclusion Criteria

• Pregnancy
• Evidence of nodal or distant metastases
• History of other malignancy with concern for renal metastasis
• Known allergy to technetium or sestamibi

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Preoperative 99mTc-Sestamibi SPECT/CT	Preoperative 99mTc-Sestamibi SPECT/CT	-

Primary Outcome Measures

Name	Time	Method
Correlation of preoperative 99mTc-sestamibi SPECT/CT findings with tumor histology following surgical resection.	Within 2 weeks of surgery

Trial Locations

Locations (1)

Johns Hopkins Hospital; 🇺🇸 Baltimore, Maryland, United States